{
    "nctId": "NCT03232593",
    "briefTitle": "A Study of Atezolizumab (Tecentriq\u00ae) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)",
    "officialTitle": "Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)",
    "overallStatus": "COMPLETED",
    "conditions": "Urothelial Carcinoma, Carcinoma, Non-Small Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Carcinoma, Hepatocellular Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1758,
    "primaryOutcomeMeasure": "Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants who are administered with atezolizumab for the locally approved indications\n\nExclusion Criteria:\n\n* Participants with a known hypersensitivity to atezolizumab or to any of the excipients",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}